Quick Answer
Rani Therapeutics Holdings, Inc. reported Total Revenue of $1.63 million for fiscal year 2025.
Rani Therapeutics Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.63M +58.9% |
$1.03M | $0.00 | $0.00 -100.0% |
$2.72M +488.1% |
$462.0K |
| Revenue (ASC 606) | $1.63M +58.9% |
$1.03M | $0.00 | $0.00 -100.0% |
$2.72M +488.1% |
$462.0K |
| Net Income | -$29.67M +1.1% |
-$30.02M +11.6% |
-$33.97M -11.1% |
-$30.59M -267.2% |
-$8.33M | — |
| Diluted EPS | -$0.45 +57.1% |
-$1.05 +21.1% |
-$1.33 -3.9% |
-$1.28 -197.7% |
-$0.43 | — |
| Total Assets | $58.62M +60.0% |
$36.63M -36.7% |
$57.92M -46.4% |
$108.03M -13.0% |
$124.21M +56.4% |
$79.42M |
| Cash and Equivalents | $18.62M +394.9% |
$3.76M -35.8% |
$5.86M -78.3% |
$27.01M -77.0% |
$117.45M +60.8% |
$73.06M |
| Long-Term Debt | $0.00 -100.0% |
$9.61M -60.7% |
$24.48M -16.0% |
$29.15M | $0.00 -100.0% |
$2.41M |
| Stockholders Equity | $33.01M +1557.1% |
$1.99M -84.5% |
$12.87M -65.1% |
$36.85M -22.3% |
$47.41M +141.8% |
-$113.34M |
| R&D Expense | $20.20M -24.3% |
$26.68M -32.7% |
$39.62M +8.2% |
$36.61M +38.2% |
$26.48M +119.9% |
$12.04M |
| Operating Income | -$38.31M +28.1% |
-$53.31M +19.3% |
-$66.10M -4.2% |
-$63.45M -23.0% |
-$51.60M -211.9% |
-$16.54M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$5.41M | +20.2% | +19.1% |
| Diluted EPS | September 30, 2025 | -$0.12 | +50.0% | +33.3% |
| Total Assets | September 30, 2025 | $10.14M | -76.7% | -40.0% |
| Cash and Equivalents | September 30, 2025 | $4.14M | -3.1% | -59.4% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | -$7.86M | -351.9% | -41.0% |
| R&D Expense | September 30, 2025 | $3.22M | -47.8% | -41.5% |
| Operating Income | September 30, 2025 | -$7.26M | +38.5% | +30.9% |
- Rani Therapeutics Holdings, Inc. reported Total Revenue of $1.63 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +58.9% in Total Revenue compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Revenue (ASC 606) of $1.63 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +58.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Net Income of -$29.67 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +1.1% in Net Income compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Diluted EPS of $0.45 per share (loss) for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +57.1% in Diluted EPS compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Total Assets of $58.62 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +60.0% in Total Assets compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Cash and Equivalents of $18.62 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +394.9% in Cash and Equivalents compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Stockholders Equity of $33.01 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +1557.1% in Stockholders Equity compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported R&D Expense of $20.20 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed a decrease of -24.3% in R&D Expense compared to the prior fiscal year.
- Rani Therapeutics Holdings, Inc. reported Operating Income of -$38.31 million for fiscal year 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +28.1% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: